Linked here is a detailed quantitative analysis of Abbvie Inc. (ABBV). Below are some highlights from the above linked analysis: Company Description: Abbvie Inc. is a global research-based pharmaceuticals business that emerged as a separate entity following its spin-off from Abbott Laboratories at the start of 2013. AbbVie's key drug is Humira for rheumatoid arthritis.
Peers: The company's peer group includes: Merck & Co. Inc. (MRK) with a 2.7% yield, Bristol-Myers Squibb Company (BMY) with a 3.5% yield, and Eli Lilly & Co. (LLY) with a 1.0% yield. Conclusion: ABBV earned one Star in the Fair Value section, earned two Stars in the Dividend Analytical Data section and earned one Star in the Dividend Income vs. MMA section for a total of four Stars. This quantitatively ranks ABBV as a...
Source: Dividend Growth Stocks
Related Articles:
Dividend Growth Stocks News
- How Dividend Stocks Can Supercharge Your Retirement Income - Nasdaq - 5/30/2025
- 2 Undervalued Dividend Stocks Passive Income Investors Can Buy Right Now - The Globe and Mail - 5/30/2025
- 3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - Yahoo Finance - 5/30/2025
- Greg Newman's Market Outlook: North American Equities and Dividend Stocks - BNN Bloomberg - 5/30/2025
- 2 Undervalued Dividend Stocks Passive Income Investors Can Buy Right Now - MSN - 5/30/2025
- Genuine Parts Company (GPC) Dividend Stock Analysis - 5/30/2025
- AFLAC Incorporated (AFL) Dividend Stock Analysis - 5/23/2025
- Automatic Data Processing Inc. (ADP) Dividend Stock Analysis - 5/16/2025
- Air Products and Chemicals Inc. (APD) Dividend Stock Analysis - 5/9/2025
- Waste Management, Inc. (WM) Dividend Stock Analysis - 5/2/2025
Abbvie Inc. (ABBV) Dividend Stock Analysis
Posted by D4L | Thursday, July 20, 2023 | ArticleLinks | 0 comments »________________________________________________________________
Subscribe to:
Post Comments (Atom)
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.